Press "Enter" to skip to content

Biomarker Tests for Molecularly Targeted Therapies Need Better Evidence, Oversight

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions, says a new report by the National Academies of Sciences, Engineering, and Medicine.

Be First to Comment

Leave a Reply

%d bloggers like this: